Posted by AGORACOM
at 1:30 PM on Friday, December 11th, 2020
SPONSOR: Thoughtful Brands is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business Thoughtful is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here For More Info
Lawmakers took a step Monday to reduce penalties for possession of magic mushrooms, a criminal justice reform move that also brings them closer to passing a bill to guide the marijuana industry in New Jersey.
The Assembly Judiciary Committee voted 4-1 with one abstention to advance the bill (A5084). It does not decriminalize psilocybin, but makes possession of up to one ounce a disorderly persons offense rather than a third degree crime. That would drop penalties to a maximum of a $1,000 fine and six months in jail.
Currently, those convicted can face between three and five years in prison.
“It’s much simpler than what appears on the surface,” Assemblyman James Kennedy, D-Union, who sponsored the bill, said during Monday’s hearing. “This is really a downgrading of the charges.”
The move to legalize marijuana has been underway in New Jersey since 2014, but mushrooms only came up last month.
As lawmakers sought to pass a bill that would end arrests for up to six ounces of marijuana, Sen. Nicholas Scutari, D-Union, added a provision to downgrade penalties for psilocybin.
The measure passed the Senate by a vote of 29-4, but the Assembly did not put the amended bill for a full floor vote. The mushrooms came unexpectedly and took away from bill’s goal of ending tens of thousands of annual marijuana arrests that disproportionately involve minorities, some said.
Last week, Kennedy introduced the new bill to separate magic mushrooms. That cleared the way for conversations to resume on both the marijuana decriminalization bill and the bill that will establish rules and regulations for the legal industry.
Lawmakers came to a compromise on the setting rules for a new marijuana industry late Friday, and plan to hold a full vote on the legislation on Dec. 17. The Senate will have to repass its decriminalization bill without the mushroom provision and move on its own version.
New Jersey is not the first state to reconsider its laws on psychedelic mushrooms.
Colorado voted to decriminalize mushrooms in 2019 and Oregon voted this November to legalize their use for medicinal purposes. Several cities in California as well as Washington, D.C., have moved to end arrests over mushroom possession.
Some studies show promising medical benefits of psilocybin to treat depression and anxiety, particularly in cancer patients or others with chronic illnesses, like HIV, Mathew Johnson, a professor of psychiatry at and behavioral sciences at Johns Hopkins Medicine, said during the hearing.
He also said psilocybin carries no risk of an overdose, and the greatest risk comes from people making poor choices while impaired, or from people with certain psychological issues like schizophrenia having adverse reactions.
“When you include it even amongst a large group of legal and illegal drugs…psilocybin mushrooms always falls towards the bottom of the rankings in terms of harms to self or harms to others,” he said.
Some lawmakers remained hesitant.
“I think the bill sends the message to young people in our state that the recreational use and misuse of these substances is really not that big a deal,” said Christopher P. DePhillips, R-Bergen, who voted no on the bill.
Those in favor reiterated that the bill would not legalize or decriminalize the use of psilocybin, but would carry a punishment that more closely fit the crime.
“We open up job opportunities to so many folks who may have done this as a one-off, and then suffered with a life-long third degree indictable conviction,” said Assemblyman Raj Mukherji, D-Hudson.
“I think that public policy will be better served by treating this as a criminal act, but as a disorderly persons offense,” he said.
Posted by AGORACOM-JC
at 7:11 AM on Thursday, December 10th, 2020
Announced that further to the news release dated March 30th , 2020, its 100% owned subsidiary, Venom Extracts has achieved its second of two revenue milestones in accordance with the terms of the definitive agreement that was entered in connection with the acquisition of Venom by the Company
On December 9th , 2020, Venom achieved the second and final revenue milestone by generating in excess of CDN $40,000,000 of revenue calculated from January 1 st , 2020.
VANCOUVER, BC , Dec. 10, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTCPK: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 230 dispensaries throughout California , and over 80 dispensaries throughout Arizona , is pleased to announce that further to the news release dated March 30 th , 2020, its 100% owned subsidiary, Venom Extracts (” Venom “) has achieved its second of two revenue milestones in accordance with the terms of the definitive agreement that was entered in connection with the acquisition of Venom by the Company (the ” Transaction “).
On December 9 th , 2020, Venom achieved the second and final revenue milestone by generating in excess of CDN$40,000,000 of revenue calculated from January 1 st , 2020. Hollister also reports that Venom generated CDN$ 4.8 million in adjusted EBITDA over the same period. As a result, the Company will issue 9,870,018 common shares (the ” Earn-Out Shares “) to certain former Venom shareholders at a deemed price of $0.20 per Earn-Out Share. The Earn-Out Shares will not be subject to any hold period under applicable securities laws.
On November 4 th the state of Arizona passed Prop 207 authorizing the Adult Use of Cannabis. Arizona is a mature, limited license medical market with 123 Operational Dispensaries as of 10/31/20, and 287,715 patients reported as of September 2020 . “The victory also puts Arizona on pace to create one of the biggest new marijuana markets in the country. The Arizona recreational market could generate as much as USD $375 million – $400 million in its first year and $700 million – $760 million by 2024, according to projections by Marijuana Business Daily.”
Venom Extracts is a leading concentrate brand in Arizona , accounting for between 25-30% of category sales. Venom has 8 sku’s with varying product forms including; Shatter, Crystals, Nectar Sauce, Sugar Wax, Live Resin, Diamond Sauce , THC-A, and Vape Cartridges. Venom products can be found in over 80 retail locations including Arizona’s market leader; Harvest Health and Recreation (CSE:HARV, OTCMKTS: HRVSF), leading multi-state cannabis operator Curaleaf (CSE:CURA, OTCMKTS: CURLF), MUV by Atlmed and other leading dispensaries.
“We are very proud of the Arizona team and their ability to achieve this final revenue milestone and market leadership position. We look forward to continuing the growth of our Arizona platform as it transitions to an adult use market.” shared Carl Saling , CEO of Hollister .
None of the securities to be issued pursuant to the Transaction have been or will be registered under the U.S. Securities Act of 1933, as amended (the ” U.S. Securities Act “), or any state securities laws, and any securities issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities issued under an exemption from the registration requirements of the U.S. Securities Act will be “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.
The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.
Non-IFRS Financial Measures: This news release makes reference to certain non–IFRS financial measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. These measures are provided as additional information to complement the IFRS financial measures by providing further metrics to understand the Company’s results of operations from management’s perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. We use non–IFRS financial measures, including segmented revenue and adjusted EBITDA, to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures.
Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com
Posted by AGORACOM
at 9:37 AM on Tuesday, December 8th, 2020
SPONSOR: Harborside is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments, Retail Dispensaries, Cultivation and Processing and Wholesale Sales (including branded product sales). Harborside operates the only drive through dispensary in California
SAN DIEGO — On Friday the United States House of Representatives passed a bill decriminalizing marijuana at the federal level. Although it is unlikely to pass the Senate, it has industry leaders here in California excited that the conversation towards decriminalization is rolling in Washington.
After receiving some rare bi-partisan support, the Marijuana Opportunity Reinvestment and Expungement or MORE Act passed the House of Representatives by a large margin. Highlights of the bill include:
Decriminalizing marijuana federally
Establishing a 5% federal tax on all cannabis products
Prohibiting the denial of federal benefits to people convicted of cannabis-related crimes
The bill would start the process of expunging the records of those convicted of Cannabis-related offensives
Will Senn is the founder of Urbn Leaf, a marijuana dispensary in San Diego. He says that the bill has been a long time coming and that it was a historic win for the industry. He went on to say that attitudes towards marijuana are shifting around the country. “I think the writing is on the wall, right? Everybody is voting for cannabis legislation nationwide. You had five more states pass some legislation in the last election year. There’s a number of upcoming bills in the near future here.”
Marijuana has been decriminalized in California since 1996 but attitudes about the plant differ drastically around the country. According to the FBI and the Pew Research Center, in 2018 40% of the 1.65 million drug arrests from around the country were marijuana-related and 92% of them were for possession.
Jason Ortiz from the Minority Cannabis Business Association said, “So, I mean, there are thousands at the very minimum, especially on the federal level. But as you start to extend the impact statewide, it could be upwards of millions of records that would get affected.”
Ortiz added that the potential expungement of cannabis-related crimes off a person’s record could change the lives of thousands of people, “And having that on your record denies you access to housing, to jobs, to other sorts of social services.”
Although the bill passed in the House, it’s unlikely that it will see a vote in the Senate. Still, business owners like Senn see it as an important benchmark of just how far the conversation around decriminalizing marijuana has come since he entered the industry.
Posted by AGORACOM-JC
at 9:32 AM on Tuesday, December 8th, 2020
Announced marketed public offering of 5,966,900 units of the Company at a price of $0.85 per Unit, for gross proceeds of $5,071,865
Each Unit is comprised of one common share of the Company and one-half of one common share purchase warrant of the Company
Each Warrant is exercisable for one Common Share at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering
TORONTO, ON , Dec. 8, 2020 – Avicanna Inc. (” Avicanna “, or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce the closing of its previously announced marketed public offering of 5,966,900 units (the ” Units “) of the Company at a price of $0.85 per Unit, for gross proceeds of $5,071,865 (the ” Offering “). Each Unit is comprised of one common share of the Company (each a ” Common Share “) and one-half of one common share purchase warrant of the Company (each full warrant, a ” Warrant ” and collectively the ” Warrants “). Each Warrant is exercisable for one Common Share at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering.
The Offering was conducted on a “best efforts” basis by a syndicate of agents led by Echelon Wealth Partners Inc., as lead agent and sole-bookrunner, and including Beacon Securities Limited and Canaccord Genuity Corp. (collectively, the ” Agents “).
Aras Azadian , CEO of Avicanna, commented: “The completion of our first prospectus offering and substantial capital raise since our IPO is a confirmation of the on-going support from our existing and new shareholders during a difficult time in the market. This also coincides with further cost reductions and with the launch of our medical products and several other commercial initiatives across several markets where we intend to use the use the proceeds of this raise to pave the way to sustainability and profitability.”
The Company has granted the Agents an option, exercisable in whole or in part, at the sole discretion of the Agents, at any time for a period of 30 days from and including the closing of the Offering, to purchase from the Company up to an additional 15% of the Units sold under the Offering, on the same terms and conditions of the Offering to cover over-allotments, if any, and for market stabilization purposes (the ” Over-Allotment Option “). The Over-Allotment Option may be exercised by the Agents to purchase additional Units, Common Shares, Warrants or any combination thereof.
The Company intends to use the net proceeds of the Offering for product development, working capital and general corporate purposes.
The securities described in this press release have not been and will not be registered under the United States Securities Act of 1933 , as amended (” U.S. Securities Act “) or any state securities laws. Accordingly, the securities may not be offered or sold in the United States (as such term is defined in Regulation S under the U.S. Securities Act) or to, or for the account or benefit of, a U.S. person (as such term is defined in Regulation S under the U.S. Securities Act) except pursuant to transactions exempt from registration under the U.S. Securities Act and under the securities laws of any applicable state. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States .
About Avicanna Inc.
Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:
Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.
With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.
Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta , Colombia . Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020 , Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia .
Stay Connected
For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected] .
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by the Company, including satisfaction of regulatory requirements in various jurisdictions, exercise of the Over-Allotment Option and the use of proceeds from the Offering.
Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .
Posted by AGORACOM
at 12:28 PM on Friday, December 4th, 2020
SPONSOR: Thoughtful Brands is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business Thoughtful is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here For More Info
Makers of CBD foods and supplements no longer face the prospect of a blanket ban in Europe after the European Commission revised its preliminary stance that CBD should be treated as a narcotic.
The Commission sent a statement to the European Industrial Hemp Association and at least one other Novel Food authorization applicant on Wednesday that hemp-derived cannabidiol should not be regulated as a narcotic and therefore can qualify as a food.
The decision comes as a relief to Europe’s hemp industry, reassuring processors and manufacturers that their CBD edible products will not be banned from the EU market.
CBD was included in the EU’s Novel Food Catalogue in January 2019, and since then has required extensive testing and authorization from food safety authorities before it can be included in products and marketed as food across the bloc’s 27 member states.
The European Commission, the executive branch of the European Union, said in July it had stopped reviewing applications for pre-market authorization of CBD products while it decided whether CBD should be regulated as a narcotic.
The Commission cited last month’s Court of Justice ruling, which said CBD derived from the entire hemp plant is not a narcotic under an international drug treaty and is therefore subject to EU law on the free movement of goods among member states.
The Commission’s full statement to Novel Food authorization applicants reads as follows:
“In light of the comments received from applicants and of the recent Court’s judgment in case C-663/184, the Commission has reviewed its preliminary assessment and concludes that cannabidiol should not be considered as drug within the meaning of the United Nations Single Convention on Narcotic Drugs of 1961 in so far as it does not have psychotropic effect. As a consequence, cannabidiol can be qualified as food, provided that also the other conditions of Article 2 of Regulation (EC) No178/2002 are met.”
Posted by AGORACOM
at 1:03 PM on Thursday, December 3rd, 2020
SPONSOR: Harborside is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments, Retail Dispensaries, Cultivation and Processing and Wholesale Sales (including branded product sales). Harborside operates the only drive through dispensary in California
This week the U.S. House of Representatives is expected to vote on a bill that would remove marijuana from the Controlled Substances Act and require federal courts to expunge many prior marijuana offenses. It will be the first time the full House will vote on ending the federal prohibition of cannabis.
Morgan Fox with the National Cannabis Industry Association says House passage would “send a really strong message to not only the rest of Congress, but to a lot of other states that the time to end prohibition has come.”
The Marijuana Opportunity Reinvestment and Expungement Act (MORE Act), introduced by Rep. Jerry Nadler (D., N.Y.), would eliminate conflict between state and federal law and allow states to set their own marijuana policies.
“We don’t need to have one size fits all. We just need to get rid of prohibition and then let the states do what the states are doing. It’s essentially what the states have done already. They haven’t waited for the federal government, which is why we have a lot of these discrepancies and challenges,” said Rep. Earl Blumenauer (D., Ore.), who has long pushed for marijuana legalization.
Blumenauer and Rep. Barbara Lee (D., Calif.) — who also wrote parts of the legislation — told Yahoo Finance the bill is a racial justice issue.
“It’s coming at a time when Americans are recognizing how hopelessly flawed the criminal justice system is,” said Blumenauer.
‘You’ve got to repair the damage’
The MORE Act would impose a 5% sales tax on marijuana and marijuana products. The revenue would go toward a new trust fund for grant programs designed to help people “adversely impacted by the War on Drugs” access job training, re-entry services, legal aid, treatment and more. The bill would also provide protections prohibiting denial of federal benefits based on use, possession or conviction for a marijuana offense.
“Regardless of who you are, if you’ve been incarcerated and if you’ve done your time and you get out, you should be provided for a second chance,” Lee told Yahoo Finance. “When you’ve been incarcerated or when you have have a record based on unjust laws — they’re really targeted in many ways, Black and Brown people — then you’ve got to make restitution, you’ve got to repair the damage. This fund is about the time that was lost because of barriers to employment, because of incarceration.”
The MORE Act would open up more opportunities for marijuana businesses, including access to Small Business Administration funding. It would also require the Bureau of Labor Statistics to gather demographic data on cannabis business owners and employees to ensure people of color and economically disadvantaged people are taking part in the industry.
“That really sets out a process for equity in the industry. This is a job-creating industry, and it also provides economic opportunities for minority-owned business owners,” said Lee.Graphic by David Foster/Yahoo Finance
The House Judiciary Committee passed the MORE Act last year 24 to 10 — Rep. Matt Gaetz (R., Fla.) and Rep. Tom McClintock (R., Calif.) were the only Republicans who voted for the bill.
In an interview with Yahoo Finance, McClintock said while he didn’t endorse marijuana, it’s clear U.S. marijuana laws have “not accomplished their goals.”
“These laws have done far more harm than good. They’ve created a violent underground economy and ruined the lives of so many young people who’ve had a youthful marijuana conviction, follow them and ruin their lives,” said McClintock.
The House was scheduled to vote on the bill in September, but Democratic leadership postponed the vote because some members in tight races worried passing the MORE Act before a stimulus package could hurt them at the polls.
Nearly a month after the election, there is still no additional coronavirus relief and many Republicans are again slamming Democrats for what they see as prioritizing the cannabis bill over coronavirus relief efforts.
Democrats have already passed two versions of the Heroes Act and argue it’s the Trump administration and Republican Senate that’s holding up stimulus talks.
Posted by AGORACOM-JC
at 4:13 PM on Wednesday, December 2nd, 2020
SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: ONN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.
CBD Oil and Skin Care: What You Need To Know
Research shows that CBD oil has anti-inflammatory properties that are beneficial to skin health.
As such, CBD can be an active ingredient in skincare products that help treat or manage acne and other related breakouts. It is an ideal option for people with reactive skin.
Since CBD oil is plant-derived produce, thus, it having antioxidative abilities should not be surprising.
The antioxidants can help reduce the signs and impacts associated with aging.
The properties counteract free-radicals therein, reducing any inflammation while diminishing noticeable signs like reddish skin tone, wrinkles, and dullness.
CBD oil is one of the active ingredients in skincare products that help to manage everything from wrinkles to acne. But is this hemp or marijuana extract as effective as touted? Does it offer any benefits, or is it marketing hype? Below are the facts about CBD gummies and CBD skincare that you need to know.
What Is CBD Oil?
CBD (cannabidiol) is a non-intoxicating compound found in hemp and marijuana plants, extracted in powder form. It is then processed with oil like coconut or olive to enhance its effectiveness as a skincare oil product.
CBD oil made for skincare will not evoke the “high” associate with its counterpart compound THC (tetrahydrocannabinol). While both CBD and THC can be found in hemp and marijuana plants, the hemp plant has a higher CBD and lower THC content than marijuana. At times the THC is so low that it not detectable during testing.
You should not mistake hemp-based CBD oil for hemp seed oil, another effective ingredient found in skincare products. At times, the two are marketed interchangeably, but the CBD oil has a high cannabidiol concentration while hemp seed oil has trace amounts or none.
The FDA regulated the name “CBD” used on products that claim to contain cannabidiol to state the same on the label. The regulated labeling is known as INCI (International Nomenclature of Cosmetic Ingredients). Therefore, products with names, such as CBD-enriched hemp seed oil, might not contain cannabidiol. You can be confident of what you buy is as specified on its label.
CBD For Acne-Prone Skin
According to research, acne is an inflammatory skin condition that could be triggered by various factors. Hence, some people can develop this inflammatory condition because of something they apply or even consume. Studies show that anything that can reduce the swelling and soothe the skin can help manage or treat acne. That is where CBD becomes an alternative solution that can fight the breakouts.
Research shows that CBD oil has anti-inflammatory properties that are beneficial to skin health. As such, CBD can be an active ingredient in skincare products that help treat or manage acne and other related breakouts. It is an ideal option for people with reactive skin.
CBD has been found to potentially lower sebum production, which is a unique quality that can help balance the sebum flow in the skin. But with this encouraging news, scientists still say that more studies are needs for conclusive findings that confirm the full extent of CBD’s benefits in skincare and overall health and wellness.
CBD Oil For Wrinkles And Anti-Aging
Since CBD oil is plant-derived produce, thus, it having antioxidative abilities should not be surprising. The antioxidants can help reduce the signs and impacts associated with aging. The properties counteract free-radicals therein, reducing any inflammation while diminishing noticeable signs like reddish skin tone, wrinkles, and dullness.
With other antioxidant-rich products in the market, it is unwise to claim that CBD is the best option out there. It is one of the many options worth considering if you are keen on finding a safe and better solution to caring for your skin.
CBD Oil For Sensitive Skin
CBD oil is claimed to have soothing compounds since it has been found to have skin-normalizing and skin-calming effects. Such properties are essential in treating and managing skin sensitivity and other related issues like inflammation, reactivity, and redness. With the skin exposed to the elements, different skin types are affected differently by environmental stressors. By applying CBD oil, its soothing mechanism will help keep the skin in check.
Posted by AGORACOM
at 11:28 AM on Wednesday, December 2nd, 2020
SPONSOR: Thoughtful Brands is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business, Thoughtful is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe
‘CBD doesn’t appear to have any … harmful effect on human health,’ the judges wrote.
The European Union’s highest court ruled today that cannabidiol (CBD) isn’t a narcotic drug.
The decision by the Court of Justice of the European Union (CJEU) is a setback for EU countries that are cracking down on CBD products, arguing they are harmful to people’s health.
At issue was a French case against a Czech company that sold CBD extracted from the whole cannabis plant to use in electronic cigarette cartridges. France only allows extraction from cannabis seeds and fiber — not the whole plant.
The court ruled the law that prompted this legal action against the Czech producers was an unnecessary restriction of the free movement of goods because the substance doesn’t pose a threat to human health.
“A decision to prohibit the marketing of CBD, which indeed constitutes the most restrictive obstacle to trade in products lawfully manufactured and marketed in other [EU] Member States, can be adopted only if that risk appears sufficiently established,” the court wrote.
First, the court set aside EU regulations on hemp — cannabis with less than 0.2 percent of the psychoactive cannabinoid tetrahydrocannabinol (THC) — in the bloc’s Common Agricultural Policy (CAP), because CBD “cannot be considered an agricultural product.”
Second, the court wrote that while countries can prohibit the free movement of goods of a banned substance like narcotic drugs, this prohibition doesn’t apply to CBD — because the substance isn’t a narcotic drug.
For example, it noted, two key U.N. conventions that classify various narcotics don’t specifically mention CBD, although they do mention “cannabis extracts.”
Banning the sale of CBD products because they’re a cannabis extract goes against the “general spirit” of the U.N. conventions, which aim to protect people’s health. CBD, unlike the psychoactive THC, “does not appear to have any psychotropic effect or any harmful effect on human health,” the court wrote.
The court conceded that a country can inhibit the free movement of goods on the basis of “public interest … provided that that legislation is appropriate … and does not go beyond what is necessary.” But such restrictions aren’t justified in this case, it said. As an example, it cited how France has not banned synthetic CBD, which has the same properties but is just not produced using the entire cannabis plant.
The court concluded that France isn’t required to prove that CBD is dangerous like narcotic drugs, but the country’s court must look at scientific data to ensure “the real risk to public health” is not “based on purely hypothetical considerations.”
Cannabis advocates hope that the ruling could set the groundwork for a legal CBD market. Currently, many CBD products in the EU are sold in a legal grey zone that allows cannabis to be sold for agricultural purposes.
Béchir Saket, vice president of the French cannabis advocacy group L630, said that the ruling was a “slap in the face” to France and prohibition of CBD in Europe. France in particular has fought against CBD products by shutting shops and prosecuting people who sell them.
“Many shops had been closed,” Saket said in an email. “Many managers and sometimes their families were taken into police custody or had their homes searched. [But today], the ECJ has ruled in our favour. It is a European decision that secures the CBD market.”
Posted by AGORACOM
at 6:09 PM on Wednesday, November 25th, 2020
OAKLAND, Calif. and TORONTO, Nov. 25, 2020 /CNW/ – Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, announced today that the nominees set forth in the Company’s Management Information Circular dated October 26, 2020, Mr. Matthew Hawkins, Mr. Kevin Albert, Mr. Michael Dacks, Mr. Peter Kampian, Mr. Alexander Norman, Mr. James Scott, and Mr. Andrew Sturner, were elected as directors of the Company at the annual meeting of shareholders held today (the “Meeting”). At the Meeting, shareholders also approved the re-appointment of MNP LLP as the auditor of the Company, Harborside’s Equity Incentive Plan, and a special resolution approving certain housekeeping amendments to the articles of the Corporation.
“On behalf of the entire Board, I’d like to thank our shareholders for their overwhelming support and for placing their trust in us to lead Harborside through its next phase of growth,” said Matthew K. Hawkins, Chairman of Harborside. “With a strengthened leadership team in place, we will work together to leverage our high-quality products and brands to accelerate our momentum and drive strong shareholder value. I look forward to updating you as we execute on the opportunity ahead.”
Harborside Inc. is one of the oldest and most respected cannabis retailers in California, operating three of the major dispensaries in the San Francisco Bay Area, a dispensary in the Palm Springs area outfitted with Southern California’s only cannabis drive-thru window, a dispensary in Oregon and a cultivation/production facility in Salinas, California. Harborside has played an instrumental role in making cannabis safe and accessible to a broad and diverse community of California consumers. Co-founded by Steve DeAngelo and dress wedding in 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States and today holds cannabis licenses for retail, distribution, cu
ltivation, nursery and manufacturing. Harborside is currently a publicly listed company on the CSE trading under the ticker symbol “HBOR”. Additional information regarding Harborside is available under Harborside’s SEDAR profile atwww.sedar.com.
Posted by AGORACOM
at 12:54 PM on Wednesday, November 25th, 2020
Harborside Inc (CSE: HBOR) is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments that generated record gross revenue in the 3rd quarter 2020.
Harborside operates the only drive through dispensary in California and is one of the oldest and most respected cannabis retailers in California:
Operations have generated over $400M in cumulative sales since inception
Generated 21.2% Sequential Revenue Growth Q3
Record Gross Revenues of $19.6 Million
Expects Full Year Gross Revenues of Approximately $61 Million – $63 Million from 5 dispensaries
OPERATIONS:
California Focused
Harborside dispensaries have generated over $400M in sales to date, and are strategically focused on growing market share in California.
The SF Bay Area cannabis market is expected to grow from ~$667M in 2018 to ~$1.5B in 20221
Market potential & growth for California eclipses the combined value of FL, NY, MA & NV
RETAIL OPERATIONS
Harborside dispensaries are preeminent NorCal cannabis retail operations with a significant track record and expertise gained through 13 years of operations.
Retail operations command 3% of California’s entire retail market
Harborside operates five dispensaries that are expected to produce approximately $62M in sales in 2020.
Significant market share and captive shelf space drive industry-leading sales
Recently opened two new Harborside locations to further expand California footprint
Watch the Video to see how Harborside works:
Harborside is an advertising client of AGORA Internet Relations Corp.
